Can Y. Zhang

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: December 08, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.

The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.

Journal: Blood
Published: May 08, 2025

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Journal: Blood
Published: May 08, 2025

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.

Journal: Blood
Published: April 08, 2024

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology
Published: January 10, 2024

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Journal: Nature communications
Published: October 23, 2023

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: May 10, 2023

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Journal: Blood
Published: February 09, 2023

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Journal: Nature communications
Published: August 24, 2022
Showing 1-12 of 22

Last Updated: 09/26/2026